Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study by M. W. M. van der Poel et al.
ORIGINAL ARTICLE
Factors that influence treatment decision-making in elderly
DLBCL patients: a case vignette study
M. W. M. van der Poel1 & W. J. Mulder2 & G. J. Ossenkoppele3 & E. Maartense4 &
M. Hoogendoorn5 & P. Wijermans6 & H. C. Schouten1
Received: 7 February 2015 /Accepted: 18 March 2015 /Published online: 14 April 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Elderly patients with diffuse large B-cell lympho-
ma (DLBCL) are frequently not treated with standard
immunochemotherapy, and this influences survival negative-
ly. The purpose of this study was to gain more insight into
treatment decision-making by hematologists. Case vignettes
concerning patients with DLBCL were presented to hematol-
ogists in the Netherlands. Patient characteristics (age, comor-
bidity) differed per case. Respondents were asked in each case
if they would treat the patient with curative intent by means of
full-dose chemotherapy or chemotherapy with dose reduction
or if they would not treat the patient with curative intent. The
vast majority of respondents would treat an elderly patient
diagnosed with DLBCL without a relevant medical history
with full-dose chemotherapy irrespective of age. In the pres-
ence of comorbidity, lack of social support, cognitive disor-
ders, and untreated depression dose reductions in advance are
frequently applied or patients are not treated with curative
intent. This is most pronounced for patients aged older than
80 years. Respondents working in a university hospital more
frequently refrain form full-dose chemotherapy with curative
intent compared to respondents working in tertiary medical
teaching hospitals or general hospitals. Patients without a rel-
evant medical history are generally treated with curative intent
irrespective of age. Cognitive disorders, comorbidity, and de-
pression reduce the change of being treated with curative in-
tent. This is most prominent in the eldest patient category.
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Introduction
The incidence of non-Hodgkin’s lymphoma (NHL) increases
with age, and currently, the mean age at diagnosis is 66 years
[1]. Diffuse large B-cell lymphoma (DLBCL) is the most
common type of aggressive NHL. Due to aging of the popu-
lation, clinicians will increasingly be confronted with elderly
patients diagnosed with DLBCL.
Standard treatment for patients with DLBCL consists of
rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisolone (R-CHOP). Not only in younger but also in el-
derly patients, this treatment schedule improves complete re-
mission rates and survival [2–9]. However, in daily practice,
elderly patients frequently do not receive standard
immunochemotherapy treatment [4, 7, 9–12]. Reasons for
suboptimal treatment are comorbidity and poor performance
status, but also high age alone is adduced as an argument to
refrain from standard treatment [4, 7, 10–12].
Little is known about the influence of patient characteristics
on treatment decision-making by clinicians. In a recent survey
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among hematologists, we observed that comorbidities, cogni-
tive disorders, and functional status are frequently taken into
consideration in treatment decision-making [13]. In the sec-
ond part of this survey, case vignettes of DLBCL patients with
varying age and extent of comorbidity were presented to the
respondents. By means of case vignettes, more information is
gathered about decision-making in the daily clinical practice.
Here, we present the results of the second part of this survey.
Methods
Data collection
Hematologists were invited to complete the online question-
naire “Treatment of the elderly with a hematologic malignan-
cy” on behalf of the Dutch-Belgian Cooperative Trial Group
for Hemato-Oncology (HOVON). HOVON is a foundation
that focuses on improving and promoting treatment methods
for adult patients with malignant hematologic disorders [14].
Hematologists were invited to participate through e-mail in
November 2011. Non-respondents were sent a reminder e-
mail within 2 months.
Study measures
The questionnaire consisted of two parts. The first part
contained questions about the importance of various factors
that play a role in the decision-making of hematologists re-
garding treatment with curative intent in elderly patients. The
results of this part were described previously [13].
In the second part of the questionnaire, case vignettes were
presented to the respondents. The survey contained a total of
11 case vignettes. All cases concerned patients with DLBCL;
however, the patient characteristics differed per case. In each
case, a distinction was made in three age categories: patients
older than 60 years, older than 70 years, and older than
80 years of age. Furthermore, the extent of comorbidity varied
per case, ranging from no comorbidity to serious comorbid
conditions. Also the social setting differed in the various
cases, from living at home without additional care to living
in a nursing home. More detailed information about the case
vignettes is provided in Appendix I. The respondents were
asked in each case if they would treat the patient with curative
intent by means of full-dose chemotherapy or chemotherapy
with dose reduction or if they would not treat the patient with
curative intent.
In addition, the respondents’ age and gender were assessed
as well as the type of hospital theywork in. In the Netherlands,
three types of hospitals can be discriminated: university hos-
pitals, tertiary medical teaching hospitals, and general hospi-
tals. Tertiary medical teaching hospitals are large teaching
hospitals, where highly specialized care is provided [15]. In
the Netherlands, 41 % of hematologists work in university
hospitals, 32 % in tertiary medical teaching hospitals, 22 %




Invitations to complete the questionnaire were sent to
255 hematologists. Eighty-six respondents participated
in the second part of the survey (33.7 % response rate).
Eighty-three respondents fully completed the second part
of the survey, and three incomplete questionnaires were
returned.
The mean age of the respondents at time of survey was
49.6 years (Table 1). There were more male than female re-
spondents. Of the respondents, 26.7 % worked in a university
hospital, 36 % in a tertiary medical teaching hospital, and
37.2 % in a general hospital.
Case vignettes: treatment according to age
and comorbidity of patients
The vast majority of respondents would treat an elderly patient
diagnosed with DLBCL without a relevant medical history
with full-dose chemotherapy irrespective of age (Fig. 1a).
However, the percentage decreased from 100 % in Byounger^
patients to 83 % in patients over 80 years old.
In the presence of mild cognitive impairment, the percent-
age of patients that would be treated with full-dose chemo-
therapy decreased in all three age categories, although most
patients would still be offered treatment with curative intent
(Fig. 1b, c). However, the decrease in treatment with curative










University hospital 23 (26.7)
Tertiary medical teaching hospital 31 (36.0)
General hospital 32 (37.2)
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intent was more pronounced in elderly patients compared to
younger patients.
The majority of respondents would not treat a patient suf-
fering from dementia with full-dose chemotherapy, regardless
of age category (Fig. 1d, e). However, younger patients with
dementia living at home with a good support system would
generally receive chemotherapy with curative intent, while
this was not the case in the oldest group of patients
(Fig. 1d). Regardless of age, a patient suffering from dementia
and living in a nursing home would generally not receive
treatment with curative intent (Fig. 1e).
Respondents would not start full-dose chemotherapy in
patients with an untreated depression in the majority of cases
irrespective of age category (Fig. 1f). In general, if a

































64 years of age
75 years of age
83 years of age
Age of pa ent
C The patient is known with mild cognitive impairment and lives at home with additional household  
care.
D The patient has dementia and lives at home with a good health care system. 
B The patient is known with mild cognitive impairment and lives at home without additional care. E The patient has dementia and lives in a nursing home.   
F The patient has a depression that has not been treated. 
Fig. 1 Case vignettes. a The patient has no relevant medical history. b
The patient is known with mild cognitive impairment and lives at home
without additional care. c The patient is known with mild cognitive
impairment and lives at home with additional household care. d The
patient has dementia and lives at home with a good health care system.
e The patient has dementia and lives in a nursing home. fThe patient has a
depression that has not been treated. g The patient has a depression that
has been treated adequately with antidepressants. h The patient is known
with diabetes mellitus 2, hypertension, and myocardial infarction and
lives at home with a good support system. i The patient is known with
diabetes mellitus 2, hypertension, and myocardial infarction and lives at
homewith no support system. jThe patient has a history ofmild cognitive
impairment, diabetes mellitus 2, hypertension, and myocardial infarction.
k The patient has a medical history with hypertension, heart failure
NYHA 3, and COPD gold 2
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depression was treated adequately, treatment was not preclud-
ed (Fig. 1g).
Patients with a history of diabetes mellitus type 2, hyper-
tension, and myocardial infarction would be treated with cu-
rative intent bymost of the respondents. However, the number
of patients treated with full-dose chemotherapy declined if
there was no social support system or concomitant mild cog-
nitive impairment (Fig. 1h–j). In the event of significant co-
morbidity, most patients would be treated with curative intent
by reduced dose chemotherapy, except for the oldest patient
category, which frequently would not be treated with curative
intent (Fig. 1k).
Case vignettes: treatment according to type of hospital
Respondents working in a university hospital more frequently
refrained from full-dose chemotherapy with curative intent in
patients of all age categories compared to respondents work-
ing in tertiary medical teaching hospitals or general hospitals
(Fig. 2a–c). Hematologists in university hospitals more fre-
quently applied dose reductions when treating with curative
intent, and in the eldest patient category, they more frequently
did not start treatment with curative intent. No major differ-
ences were found between respondents working in tertiary
medical teaching hospitals and general hospitals.
Discussion
The aim of the present study was to gain more insight into
treatment decision-making by hematologists in DLBCL pa-
tients of varying age, comorbidity, and social support by use
of case vignettes.
G  The patient has a depression that has been treated adequatelywith antidepressants.   
H  The patient is known with diabetes mellitus 2, hypertension and myocardial infarction and lives at  
home with a good support system. 
I The patient is known with diabetes mellitus 2, hypertension and myocardial infarction and lives at 
home with no support system.
J  The patient has a history of mild cognitive impairment, diabetes mellitus 2, hypertension and  
myocardial infarction.
K  The patient has a medical history with hypertension, heart failure NYHA 3 and COPD gold 2. 
Fig. 1 (continued)
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We observed that almost all respondents would treat
DLBCL patients without a relevant medical history with cu-
rative intent. In the eldest patient category, intentional dose
reductions are frequent. This is in line with the results of
previous reports [11, 13]. In a recent study among DLBCL
patients older than 75 years, dose reductions occurred in 31 %
of patients at start of treatment with R-CHOP and age was the
most important reason in 27 % of cases [4]. However, in 68 %
of patients, there was no clear argumentation.
Furthermore, we found that treatment decision-making is
to a large extent influenced by the presence of comorbidity. In
case of serious comorbidity, respondents frequently applied
dose reductions in advance or refrained from treatment with
curative intent. This is in line with the results of the first part of
this survey in the same respondents and was also observed is
previous studies [5, 9, 13, 16, 17]. In elderly patients, comor-
bidity is common and a prevalence of up to 87 % in patients
aged older than 80 years is described [10]. Comorbidity is
associated with lower survival in elderly NHL patients [9,
11, 16–21]. The impaired outcome in patients with comorbid-
ity can not only be the result of the direct impact of comor-
bidity on outcome but can also be the consequence of less
intensive treatment schedules or less treatment tolerability
[16, 22].
In addition, the results of this study showed that cog-
nitive impairment has an important influence on treat-
ment decisions. In case of mild cognitive impairment,
most patients would be treated with curative intent; how-
ever, there was a marked decrease in this percentage in
case of dementia. This was most pronounced for the
eldest patients above 80 years of age. It has been shown
that dementia is associated with an increased mortality
rate in NHL patients [9, 23].
Lastly, we observed that depression, especially when not
treated adequately, appeared to affect the treatment regime of
DLBCL patients. The prevalence of depression in DLBCL
patients is high [24]. Moreover, a study among cancer survi-
vors observed increased all-cause mortality in patients with
depressive symptoms even after adjustment for major clinical
predictors [25]. This might be explained by lower treatment
compliance in depressed patients or by a higher incidence of
depression in patients with poor performance status [26]. Ex-
pected low treatment adherence or worse coping strategies
may be reasons for clinicians to treat patients with a depres-
sion with adapted chemotherapy schedules.
Interestingly, respondents working in university hospitals
seem to treat elderly patients less often with full-dose chemo-
therapy. This might be the consequence of a referral bias, and
possibly these respondents have less experience in treating
elderly DLBCL patients.
Respondents declared that comorbidity and cognitive im-
pairment in DLBCL patients largely influence treatment deci-
sion-making. In daily clinical practice, the extent of comor-
bidity and cognitive impairment in a patient is in general
judged by the physician without performing a systematic as-
sessment, among others because the latter is time-consuming.
Clinical judgment by a physician is however less reliable in
detecting geriatric problems compared to a systematic evalu-
ation by comprehensive geriatric assessment (CGA) [27–31].
However, no large prospective randomized controlled trials
have been performed investigating the role of CGA in the
treatment of elderly DLBCL patients, and therefore, it is not
A Treatment according to type of  hospital in case of a 64 year old patient.  
B Treatment according to type of  hospital in case of a 75 year old patient.
C Treatment according to type of  hospital in case of an 83 year old patient. 
Fig. 2 Treatment according to type of hospital and to age of patient
irrespective of comorbidity. a Treatment according to type of hospital in
the case of a 64-year-old patient. b Treatment according to type of
hospital in the case of a 75-year-old patient. c Treatment according to
type of hospital in the case of an 83-year-old patient
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clear how the results of CGA might influence treatment deci-
sion-making.
The strengths of our study are that more information is
provided about factors that influence treatment decision-
making by clinicians, an important topic in cancer treat-
ment. Furthermore, by presenting case vignettes, various
situations that resemble daily clinical practice could be
studied. Moreover, hematologists of university, tertiary
medical teaching hospitals, and general hospitals partici-
pated in the study, making the results generalizable. Pos-
sible limitations of our study might be that, even though
the response rate was reasonable, especially hematologists
with a particular interest in this subject responded. In ad-
dition, it cannot be entirely excluded that in clinical prac-
tice other treatment decisions are made than that the de-
cisions that were indicated in the cases by respondents. At
last, an initial treatment decision is not fixed and it is
possible that treatment is for example intensified if treat-
ment tolerability appears to be good.
In conclusion, patients without a relevant medical history
are in general treated with curative intent irrespective of age.
However, in the presence of mild cognitive impairment, de-
mentia, comorbidity, or depression dose reductions in advance
are frequently applied or patients are not treated with curative
intent. This is most prominent in the eldest patient category.
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The patient has no relevant medical history
The patient is known with mild cognitive impairment
and lives at home without additional care
The patient is known with mild cognitive
impairment and lives at home with additional household care
The patient has dementia and lives at home with a good
health care system
The patient has dementia and lives in a nursing home
The patient has a depression that has not been treated
The patient has a depression that has been adequately treated
with antidepressants
The patient is known with diabetes mellitus 2, hypertension and
myocardial infarction and lives at home with a good support system
The patient is known with diabetes mellitus 2, hypertension, myocardial
infarction and lives at home with no support system
The patient has a history of mild cognitive impairment, diabetes mellitus 2,
hypertension and myocardial infarction
The patients has a medical history with hypertension, heart failure NYHA
3 and COPD gold 2
In the outpatient clinic, you see a 64-year-old patient who is diagnosed with diffuse large B-cell lymphoma. Could you indicate in each of the following
cases whether you would treat the patient with curative intent by means of full-dose chemotherapy or chemotherapy with dose reduction or if you would
not treat the patient with curative intent? You can also declare that you do not know. The same cases were presented to respondents for a 75-year-old and
an 83-year-old patient
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reproduction in any medium, provided the original author(s) and the
source are credited.
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